Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Applied Genetic Technologies	Fennec Pharmaceuticals	Voyager Therapeutics	Gamida Cell	LogicBio Therapeutics
Symbol	NASDAQ:AGTC	NASDAQ:FENC	NASDAQ:VYGR	NASDAQ:GMDA	NASDAQ:LOGC
Price Information
Current Price	$4.26	$6.77	$4.73	$6.44	$4.59
52 Week Range	Buy	Buy	Hold	Buy	Buy
MarketRank™
Overall Score	1.6	1.4	1.7	1.4	1.3
Analysis Score	3.5	3.5	3.1	3.5	3.5
Community Score	3.0	2.5	2.6	2.7	2.4
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	0.8	1.7	0.0	0.8
Earnings & Valuation Score	0.6	0.0	1.3	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Hold	Buy	Buy
Consensus Price Target	$17.58	$13.50	$10.55	$20.25	$17.33
% Upside from Price Target	312.75% upside	99.41% upside	123.04% upside	214.44% upside	277.63% upside
Trade Information
Market Cap	$182.56 million	$178.90 million	$182.60 million	N/A	$155.98 million
Beta	2.21	0.09	1.1	1.93	1.17
Average Volume	2,280,821	107,634	558,021	697,944	139,797
Sales & Book Value
Annual Revenue	$2.45 million	$170,000.00	$171.13 million	N/A	$3.45 million
Price / Sales	74.34	1,035.53	1.04	N/A	42.79
Cashflow	N/A	N/A	$1.06 per share	N/A	N/A
Price / Cash	N/A	N/A	4.47	N/A	N/A
Book Value	$2.76 per share	$1.12 per share	$4.12 per share	$1.44 per share	$1.93 per share
Price / Book	1.54	6.04	1.15	N/A	2.38
Profitability
Net Income	$-45,890,000.00	$-18,110,000.00	$36.74 million	$-72,700,000.00	$-32,620,000.00
EPS	($2.17)	($0.76)	$0.98	($1.66)	($1.29)
Trailing P/E Ratio	N/A	N/A	4.59	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	24.66%	N/A	N/A
Return on Equity (ROE)	-90.61%	-62.70%	29.50%	-100.66%	-80.55%
Return on Assets (ROA)	-62.13%	-57.35%	14.76%	-55.78%	-54.90%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.10%	N/A	N/A	0.82%	0.14%
Current Ratio	6.83%	9.62%	7.10%	8.97%	8.58%
Quick Ratio	6.83%	9.62%	7.10%	8.97%	8.58%
Ownership Information
Institutional Ownership Percentage	43.50%	55.24%	69.40%	N/A	54.74%
Insider Ownership Percentage	7.50%	9.68%	23.90%	N/A	23.40%
Miscellaneous
Employees	83	N/A	177	110	39
Shares Outstanding	42.76 million	26.00 million	37.73 million	24.22 million	32.16 million
Next Earnings Date	9/8/2021 (Estimated)	8/4/2021 (Estimated)	8/9/2021 (Estimated)	8/10/2021 (Estimated)	8/9/2021 (Estimated)
Optionable	Optionable	Optionable	Optionable	Not Optionable	Not Optionable

Source	Headline
	LogicBio Therapeutics (NASDAQ:LOGC) Coverage Initiated by Analysts at HC Wainwright americanbankingnews.com - June 7 at 7:08 AM
	LogicBio Therapeutics Inc (LOGC) investing.com - June 5 at 7:27 PM
	Chardan Capital Reaffirms "Buy" Rating for LogicBio Therapeutics (NASDAQ:LOGC) americanbankingnews.com - June 2 at 1:04 PM
	BRIEF-Logicbio Therapeutics Announces First Patient Dosed In Groundbreaking Phase 1/2 Sunrise Clinical Trial For The Treatment Of Pediatric Patients Suffering From ... msn.com - June 2 at 8:40 AM
	LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia finance.yahoo.com - June 2 at 8:40 AM
	LogicBio Therapeutics to Participate in Upcoming Investor Conferences finance.yahoo.com - June 1 at 7:13 PM
	LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appointments finance.yahoo.com - May 19 at 8:21 AM
	LogicBio Therapeutics' (NASDAQ:LOGC) Stock Price Has Reduced 22% In The Past Year finance.yahoo.com - May 17 at 2:38 PM
	LogicBio Therapeutics: Q1 Earnings Snapshot stamfordadvocate.com - May 10 at 8:20 AM
	LogicBio Therapeutics Strengthens Management Team with Key Appointments finance.yahoo.com - May 10 at 8:20 AM
	LogicBio Therapeutics Reports First Quarter Year 2021 Financial Results and Provides Business Update finance.yahoo.com - May 10 at 8:20 AM
	LogicBio Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting finance.yahoo.com - May 4 at 9:59 AM
	LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalonic Acidemia finance.yahoo.com - May 3 at 6:49 PM
	BRIEF-LogicBio Therapeutics Announces Strategic Collaboration And Option Agreement With Canbridge Pharmaceuticals Leveraging Gene Editing And Gene Delivery Platforms msn.com - April 27 at 2:11 PM
	LogicBio Therapeutics, CANbridge Ink Partnership For Development Of Gene Therapy Candidates finance.yahoo.com - April 27 at 2:11 PM
	LogicBio Collaborates With CANbridge Pharma; Grants Option To License LB-001 In Greater China markets.businessinsider.com - April 27 at 9:10 AM
	LogicBio Therapeutics Announces Research Collaboration with Daiichi Sankyo prnewswire.com - April 27 at 9:10 AM
	LogicBio Therapeutics Announces Strategic Collaboration and Option Agreement with CANbridge Pharmaceuticals Leveraging Gene Editing and Gene Delivery Platforms finance.yahoo.com - April 27 at 9:10 AM
	What Percentage Of LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Shares Do Insiders Own? nasdaq.com - April 24 at 6:42 PM
	Health Check: How Prudently Does LogicBio Therapeutics (NASDAQ:LOGC) Use Debt? finance.yahoo.com - March 17 at 12:29 PM
	LogicBio Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update finance.yahoo.com - March 15 at 5:56 PM
	LogicBio Announces Extension Of Collaboration With Children’s Medical Research Institute apnews.com - January 7 at 12:40 PM
	LogicBio Announces Extension Of Collaboration With Children's Medical Research Institute finance.yahoo.com - January 7 at 12:40 PM
	LogicBio Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference finance.yahoo.com - January 6 at 11:32 AM
	LogicBio Therapeutics Inc. Regi (0IF.SG) sg.finance.yahoo.com - January 1 at 10:36 PM

Date	Company	Brokerage	Action
3/1/2021	Applied Genetic Technologies	Stifel Nicolaus	Initiated Coverage
2/2/2021	Applied Genetic Technologies	HC Wainwright	Boost Price Target
2/1/2021	Applied Genetic Technologies	Roth Capital	Boost Price Target
11/20/2020	Applied Genetic Technologies	Berenberg Bank	Reiterated Rating
7/22/2020	Applied Genetic Technologies	Chardan Capital	Reiterated Rating
6/22/2020	Applied Genetic Technologies	Cantor Fitzgerald	Initiated Coverage
1/24/2020	Applied Genetic Technologies	Janney Montgomery Scott	Reiterated Rating
1/9/2020	Applied Genetic Technologies	Wedbush	Reiterated Rating
1/9/2020	Applied Genetic Technologies	BMO Capital Markets	Boost Price Target
5/28/2021	Fennec Pharmaceuticals	Maxim Group	Reiterated Rating
4/21/2021	Fennec Pharmaceuticals	Craig Hallum	Initiated Coverage
10/11/2018	Fennec Pharmaceuticals	The Goldman Sachs Group	Initiated Coverage
10/11/2018	Fennec Pharmaceuticals	Dawson James	Initiated Coverage
5/13/2021	Voyager Therapeutics	Robert W. Baird	Reiterated Rating
4/19/2021	Voyager Therapeutics	Morgan Stanley	Lower Price Target
2/3/2021	Voyager Therapeutics	BTIG Research	Downgrade
1/13/2021	Voyager Therapeutics	Canaccord Genuity	Reiterated Rating
12/23/2020	Voyager Therapeutics	Raymond James	Downgrade
11/11/2020	Voyager Therapeutics	Oppenheimer	Downgrade
11/10/2020	Voyager Therapeutics	Wells Fargo & Company	Downgrade
5/13/2020	Voyager Therapeutics	Nomura	Reiterated Rating
3/30/2020	Voyager Therapeutics	Nomura Securities	Lower Price Target
3/9/2021	Gamida Cell	Piper Sandler	Lower Price Target
3/9/2021	Gamida Cell	Needham & Company LLC	Lower Price Target
6/30/2020	Gamida Cell	Evercore ISI	Initiated Coverage
9/20/2019	Gamida Cell	JMP Securities	Initiated Coverage
11/21/2018	Gamida Cell	CIBC	Initiated Coverage
3/1/2021	LogicBio Therapeutics	William Blair	Reiterated Rating
11/13/2018	LogicBio Therapeutics	Barclays	Initiated Coverage

(Data available from 6/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources